<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184518</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-1805</org_study_id>
    <secondary_id>ESR-18-14002</secondary_id>
    <secondary_id>2019-001045-40</secondary_id>
    <nct_id>NCT04184518</nct_id>
  </id_info>
  <brief_title>Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma</brief_title>
  <acronym>CEDUVEAL-M</acronym>
  <official_title>Phase II, Open-Label Study of Preliminary Efficacy of Durvalumab (MEDI4736) in Combination With Cediranib in Patients With Metastatic Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español Multidisciplinar de Melanoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MFAR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español Multidisciplinar de Melanoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and&#xD;
      durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first&#xD;
      line of after failure to first line systemic or liver directed therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The Cediranib producer laboratory decided to stop the development of this product.&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate by RECIST 1.1</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>ORR calculated as the proportion of patient with a complete response (CR) or partial response (PR). The final statistical analysis of this endpoint is expected to be performed every 8 weeks since start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free survival (PFS) by RECIST 1.1</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>Median time between start of treatment and date of progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 12 months</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Proportion of patients alive 12 months since start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at 24 months</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>Proportion of patients alive 24 months since start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in effector CD8 T-cell response in the tumor induced by cediranib combined with durvalumab</measure>
    <time_frame>24 months after start of treatment</time_frame>
    <description>Changes in the CD8 values from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with immune-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cediranib plus durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib Maleate</intervention_name>
    <description>Cediranib 20mg, oral, 5 days on and 2 days off until disease progression</description>
    <arm_group_label>Cediranib plus durvalumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500mg, intravenous, every 4 weeks until disease progression</description>
    <arm_group_label>Cediranib plus durvalumab</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed metastatic uveal melanoma with measurable&#xD;
             disease not eligible for curative therapy.&#xD;
&#xD;
          -  Participants must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional&#xD;
             techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam.&#xD;
             Patients must have at least 1 biopsiable liver metastasis.&#xD;
&#xD;
          -  Patients can have received one prior therapy for metastatic disease, excepting for&#xD;
             treatments listed in exclusion criteria.&#xD;
&#xD;
          -  Patients must be 18 years of age or older at time of study entry.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in the&#xD;
             protocol.&#xD;
&#xD;
          -  Adequate normal organ and marrow function as defined below: Haemoglobin ≥9.0 g/dL,&#xD;
             Absolute neutrophil count (ANC) &gt; 1.5 x 109/L (&gt; 1500 per mm3), Platelet count ≥ 100 x&#xD;
             109/L (&gt;100,000 per mm3). Serum bilirubin ≤1.5 x institutional upper limit of normal&#xD;
             (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent&#xD;
             or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of&#xD;
             hemolysis or hepatic pathology), who will be allowed only in consultation with&#xD;
             Coordinating Investigator. Aspartate aminotransferase (AST) and/or alanine&#xD;
             aminotransferase (ALT) &lt;2.5 x upper limit of normal (ULN) in the absence of liver&#xD;
             metastases. If liver metastases are present, both AST and ALT must be no more than 5 x&#xD;
             ULN. Creatinine clearance &gt;30 ml/min calculated by Cockcroft-Gault or another&#xD;
             validated method. Urine protein:creatinine ratio (UPC) ≤1 or ≤2+ proteinuria on 2&#xD;
             consecutive dipsticks taken no less than 1 week apart. Subjects with 2+ proteinuria on&#xD;
             dipstick must also have UPC &lt; 0.5 on 2 consecutive samples.&#xD;
&#xD;
          -  Postmenopausal or evidence of non-childbearing status for women of childbearing&#xD;
             potential as confirmed by a negative urine or serum pregnancy test within 7 days prior&#xD;
             to inclusion. Women will be considered post-menopausal if they have been amenorrheic&#xD;
             for 12 months without an alternative medical cause. The following age-specific&#xD;
             requirements apply: Amenorrheic for ≥1 year in the absence of chemotherapy and/or&#xD;
             hormonal treatments. Luteinizing hormone (LH) and/or follicle stimulating hormone&#xD;
             and/or estradiol levels in the post-menopausal range. Radiation induced oophorectomy&#xD;
             with last menses &gt;1 year ago. Chemotherapy induced menopause with &gt;1 year interval&#xD;
             since last menses. Surgical sterilization (bilateral oophorectomy or hysterectomy)&#xD;
             Women &lt;50 years of age would be considered post-menopausal if they have been&#xD;
             amenorrheic for 12 months or more following cessation of exogenous hormonal treatments&#xD;
             and if they have luteinizing hormone and follicle-stimulating hormone levels in the&#xD;
             post-menopausal range for the institution or underwent surgical sterilization&#xD;
             (bilateral oophorectomy or hysterectomy). Women ≥50 years of age would be considered&#xD;
             post-menopausal if they have been amenorrheic for 12 months or more following&#xD;
             cessation of all exogenous hormonal treatments, had radiation-induced menopause with&#xD;
             last menses &gt;1 year ago, had chemotherapy-induced menopause with last menses &gt;1 year&#xD;
             ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral&#xD;
             salpingectomy or hysterectomy).&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
          -  Must have a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Subjects must be able to swallow and retain oral medications and be without clinically&#xD;
             significant gastrointestinal illnesses that would preclude absorption of cediranib.&#xD;
&#xD;
          -  Adequately controlled BP: Systolic BP ≤140 mmHg and diastolic BP ≤90 mmHg in the&#xD;
             presence or absence of a stable regimen of antihypertensive therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with concomitant malignancy other than non-melanoma skin cancer, or&#xD;
             superficial bladder cancer controlled with local treatment.&#xD;
&#xD;
          -  Previous treatment with anti-angiogenic agents MEK, BRAF, ERK inhibitors.&#xD;
&#xD;
          -  Previous treatment with anti-PD1/PDL1 (including durvalumab) treatments.&#xD;
&#xD;
          -  Presence of brain or leptomeningeal involvement unless previously treated, off&#xD;
             steroids at least 2 weeks, and considered stable. Patients with untreated central&#xD;
             nervous system (CNS) metastases and/or carcinomatous meningitis identified either on&#xD;
             the baseline brain imaging [RECIST]) obtained during the screening period or&#xD;
             identified prior to signing the ICF. Patients whose brain metastases have been treated&#xD;
             may participate provided they show radiographic stability (defined as 2 brain images,&#xD;
             both of which are obtained after treatment to the brain metastases. These imaging&#xD;
             scans should both be obtained at least four weeks apart and show no evidence of&#xD;
             intracranial progression). In addition, any neurologic symptoms that developed either&#xD;
             as a result of the brain metastases or their treatment must have resolved or be stable&#xD;
             either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of&#xD;
             prednisone or its equivalent and anticonvulsants, for at least 14 days prior to the&#xD;
             start of treatment. Brain metastases will not be recorded as RECIST Target Lesions at&#xD;
             baseline.&#xD;
&#xD;
          -  Patients weighing &lt;30kg will be excluded from enrollment.&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks.&#xD;
&#xD;
          -  Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study.&#xD;
&#xD;
          -  Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine&#xD;
             therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies) ≤28 days prior to the first dose of study drug If sufficient wash-out time&#xD;
             has not occurred due to the schedule or PK properties of an agent, a longer wash-out&#xD;
             period will be required, as agreed by Sponsor designated Coordinating Investigator and&#xD;
             Principal Investigator.&#xD;
&#xD;
          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria: Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis&#xD;
             after consultation with the Coordinating Investigator. Patients with irreversible&#xD;
             toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be&#xD;
             included only after consultation with the Coordinating Investigator.&#xD;
&#xD;
          -  Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment&#xD;
             different to cediranib and/or durvalumab. Concurrent use of hormonal therapy for&#xD;
             non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.&#xD;
&#xD;
          -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of&#xD;
             radiation within 4 weeks of the first dose of study drug.&#xD;
&#xD;
          -  Major surgery within a minimum of 2 weeks prior to inclusion; patients must have&#xD;
             recovered from any effects of any major surgery prior to inclusion. Note: Local&#xD;
             surgery of isolated lesions for palliative intent and minor surgeries performed to&#xD;
             obtain biological material for the study (i.e. liver biopsy) are acceptable.&#xD;
&#xD;
          -  History of allogeneic organ transplantation.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion: Patients with vitiligo or alopecia. Patients with hypothyroidism (e.g.,&#xD;
             following Hashimoto syndrome) stable on hormone replacement. Any chronic skin&#xD;
             condition that does not require systemic therapy. Patients without active disease in&#xD;
             the last 5 years may be included but only after consultation with the Coordinating&#xD;
             Investigator. Patients with celiac disease controlled by diet alone.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, compromise cediranib&#xD;
             absorption, substantially increase risk of incurring AEs or compromise the ability of&#xD;
             the patient to give written informed consent.&#xD;
&#xD;
          -  History of another primary malignancy, except for: Malignancy treated with curative&#xD;
             intent and with no known active disease ≥5 years before the first dose of IMP and of&#xD;
             low potential risk for recurrence. Adequately treated non-melanoma skin cancer or&#xD;
             lentigo maligna without evidence of disease. Adequately treated carcinoma in situ&#xD;
             without evidence of disease.&#xD;
&#xD;
          -  History of active primary immunodeficiency.&#xD;
&#xD;
          -  Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for&#xD;
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative&#xD;
             for HCV RNA.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab. The following are exceptions to this criterion: Intranasal,&#xD;
             inhaled, topical steroids, or local steroid injections (e.g., intra articular&#xD;
             injection). Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
             prednisone or its equivalent. Steroids as premedication for hypersensitivity reactions&#xD;
             (e.g., CT scan premedication).&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP.&#xD;
             Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and&#xD;
             up to 30 days after the last dose of IMP.&#xD;
&#xD;
          -  Female patients who are pregnant (confirmed with positive pregnancy test) or&#xD;
             breastfeeding or male or female patients of reproductive potential who are not willing&#xD;
             to employ effective birth control from screening to 90 days after the last dose of&#xD;
             durvalumab and or cediranib therapy.&#xD;
&#xD;
          -  History of severe allergic reaction attributed to cediranib or a similar VEGFR&#xD;
             inhibitor or known hypersensitivity to any component of cediranib dose composition.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to durvalumab or any of the durvalumab excipients.&#xD;
&#xD;
          -  History of gastrointestinal perforation. Subjects with a history of abdominal fistula&#xD;
             will be eligible if: the fistula has been surgically repaired, there is no evidence of&#xD;
             fistula for at least 6 months prior to inclusion, and the subject is deemed to be at&#xD;
             low risk of recurrent fistula in the opinion of the Investigator.&#xD;
&#xD;
          -  History of intra-abdominal abscess within 3 months prior to inclusion.&#xD;
&#xD;
          -  Clinically significant signs and/or symptoms of bowel obstruction within 3 months&#xD;
             prior to inclusion.&#xD;
&#xD;
          -  Resting ECG with clinically significant abnormal findings. i.e. Mean QT interval&#xD;
             corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3&#xD;
             ECGs (within 15 minutes at 5 minutes apart).&#xD;
&#xD;
          -  Subjects with any one or more of the following: History of myocardial infarction&#xD;
             within 6 months prior to inclusion; patients with a history of myocardial infarction&#xD;
             within 6 to 12 months prior to inclusion may be allowed following assessment. Unstable&#xD;
             angina within 6 months prior to inclusion. Known significant cardiac disease (New York&#xD;
             Heart Association [NYHA] classification of III or IV).&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; lower limit of normal (LLN) per institutional&#xD;
             guidelines, or &lt;55%, if threshold for normal is not otherwise specified by&#xD;
             institutional guidelines, for patients with the following risk factors: Prior or&#xD;
             planned treatment with anthracyclines (ie, PLD). Prior treatment with trastuzumab.&#xD;
             Prior central thoracic radiation therapy (RT), including exposure of heart to&#xD;
             therapeutic doses of ionizing RT. History of myocardial infarction within 6 to 12&#xD;
             months prior to inclusion. Prior history of other significant impaired cardiac&#xD;
             function.&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to inclusion.&#xD;
&#xD;
          -  Evidence of any other disease, physical examination or laboratory finding giving&#xD;
             reasonable suspicion of a disease or condition that puts the subject at high risk for&#xD;
             treatment-related complication.&#xD;
&#xD;
          -  Prior enrollment or treatment in a previous durvalumab and/or cediranib clinical study&#xD;
             regardless of treatment arm assignment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José M. Piulats</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Català d'Oncología L'Hospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Catalá d'Oncología L'Hospitalet</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveal melanoma</keyword>
  <keyword>cediranib</keyword>
  <keyword>durvalumab</keyword>
  <keyword>liver metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

